Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation
HB Xiao, ZL Sun, HB Zhang, DS Zhang - Pharmacological Reports, 2012 - Springer
HB Xiao, ZL Sun, HB Zhang, DS Zhang
Pharmacological Reports, 2012•SpringerBackground Inhibiting the action of proprotein convertase subtilisin/kexin type 9 (PCSK9) on
the low-density lipoprotein receptor (LDLR) has emerged as a novel therapeutic target for
hypercholesterolemia. Here we investigated the effect of berberine, natural plant extracts, on
PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced
inflammation. Methods Forty female mice were divided into four groups (n= 10): control, LPS
(5 mg/kg), LPS+ berberine 10 (5 mg/kg LPS plus 10 mg/kg berberine), and LPS+ berberine …
the low-density lipoprotein receptor (LDLR) has emerged as a novel therapeutic target for
hypercholesterolemia. Here we investigated the effect of berberine, natural plant extracts, on
PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced
inflammation. Methods Forty female mice were divided into four groups (n= 10): control, LPS
(5 mg/kg), LPS+ berberine 10 (5 mg/kg LPS plus 10 mg/kg berberine), and LPS+ berberine …
Abstract
Background
Inhibiting the action of proprotein convertase subtilisin/kexin type 9 (PCSK9) on the low-density lipoprotein receptor (LDLR) has emerged as a novel therapeutic target for hypercholesterolemia. Here we investigated the effect of berberine, natural plant extracts, on PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced inflammation.
Methods
Forty female mice were divided into four groups (n= 10): control, LPS (5 mg/kg), LPS+ berberine 10 (5 mg/kg LPS plus 10 mg/kg berberine), and LPS+ berberine 30 (5 mg/kg LPS plus 30 mg/kg berberine). Changes in the levels of blood lipids [total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C)]; pro-inflammatory cytokines [interferon-γ (IFNγ), tumor necrosis factor α (TNFα), and interleukin-1α (IL-1α)], 8-iso-prostane, hepatic expressions of PCSK9 and LDLR were determined.
Results
Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNγ, TNFα, IL-1α, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice.
Conclusion
The present results suggest that berberine inhibits dyslipidemia in C57BL/6 mice with LPS induced inflammation through regulating PCSK9-LDLR pathway.
Springer